Abraxane
What Abraxane is used for
Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Abraxane
- Active substance
- paclitaxel
- Disease area
- Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01CD01
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2008
Official information
In the USA
Same active substance: Abraxane, Paclitaxel Protein Bound Particles Albumin Bound
In India
- Paclitaxel: 136 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Abraxane used for?
Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
What is the active substance in Abraxane?
Abraxane contains paclitaxel.
Who makes Abraxane?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU